Biosimilar Labeling Variation From Reference Product OK, FDA Says

FDA appears open to more variation between the labels of a biosimilar product and its reference biologic than may have been evident in its first approval under the 351(k) pathway.

Although biosimilar labeling should incorporate relevant data and information from the reference product's labeling, there are situations in which the biosimilar labeling may be different from that of the reference...